fbpx

MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders

MindMed (NASDAQ: MNMD) (NEO: MMED) a leading biotech company developing psychedelic-inspired therapies, has agreed to work with Forian Inc. (NASDAQ: FORA), a leading provider of evidence-based support for more comprehensive clinical and commercial decision-making.

MindMed and Forian will collaborate to develop best practices for using real-world evidence (“RWE”) information to help improve the health and lives of psychiatric patients. Forian has deep domain experience in RWE and outcomes studies and has developed a variety of information products to serve the healthcare industry.

Large, real-world health datasets drive discovery and connections that can be missed in individual episodic health visits. Patterns emerge when multiple visits can be seen in a representative population.  

Our goal is to use real-world healthcare data and deep digital phenotyping to achieve in-depth, precise and personalized characterizations of individuals with generalized anxiety disorders and other conditions of interest for our drug development programs. By fully acknowledging each person’s physiology, environment, and behavioral stressors, we ultimately aim for integrated digital deep diagnoses to drive precision psychiatry for drug development and clinical treatment across our target therapeutic areas.

MindMed’s Chief Medical Officer Dan Karlin, MD MA

“Forian understands the power our real-world evidence and unique data sets add to our healthcare and pharmaceutical partners,” said Dan Barton, Chief Executive Officer of Forian. “We are thrilled to collaborate with MindMed to help them deliver insights to improve the health of psychiatric patients.”

The global pandemic and its overwhelming mental health impacts underscore the need for tailored solutions and treatments that can be administered in a preventative rather than reactive manner. MindMed is leveraging the recent advances in multi-omics, real-world data and artificial intelligence to help develop precise and personalized psychiatry tools.

About MindMed
MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop, and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

About Forian
Forian Inc. provides a unique suite of SaaS solutions, data management capabilities and proprietary data and analytics to optimize and measure operational, clinical and financial performance for customers within the traditional and emerging life sciences, healthcare payer and provider segments, as well as cannabis dispensaries, manufacturers, cultivators and regulators. For more information, please visit the Company’s website at www.forian.com.

To view the original press release in its entirety click here


You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More